| Your Resource for Neurotherapeutics Discovery and Development |
JOURNAL ANNOUNCEMENTASENT Announces New Partnership with Elsevier to Publish Neurotherapeutics, Beginning January 2024 Neurotherapeutics’ preeminent international editorial board will continue under the leadership of Editor-in-Chief Dr. M. Maral Mouradian and ensures that this high quality, peer-reviewed journal will be an authoritative resource for the community it serves. In addition, to strive for continued quality and market growth, Neurotherapeutics will move to a fully Gold Open Access (OA) publishing model. |
ABOUT ASENT
The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.
ASENT engages in scientific exchanges to encourage contacts between those involved in the discovery and development of neurotherapeutics and to provide opportunities for dialogue between the interested groups. The society organizes education and training and publishes a journal for healthcare practitioners, scientists and officials participating in the neurotherapeutics field, which serves as a forum for its members and interested groups addressing diverse issues.
MEET THE LEADERSHIPAndrew J. Cole, M.D., F.R.C.P.(C.), our new President of ASENT. Dr. Cole is Professor of Neurology at Harvard Medical School and Director of the Massachusetts General Hospital (MGH) Epilepsy Service, Chief of the Division of Clinical Neurophysiology, and Vice Chair of the MGH Neurology Service at Massachusetts General Hospital. |
MEET THE EDITORASENT is honored to have M. Maral Mouradian, MD, as the NEUROTHERAPEUTICS journal Editor in Chief. Dr Mouradian is the William Dow Lovett Professor of Neurology; Director of the RWJMS Institute for Neurological Therapeutics; and Vice Chancellor for Faculty Development, Rutgers Biomedical and Health Sciences - Robert Wood Johnson Medical School |
MEET THE CO-CHAIRSSharon Tamir, Vice President, Head of Neuro-oncology & Myelofibrosis at Karyopharm Therapeutics Inc. and Dietrich Haubenberger, MD, Executive Medical Director for Clinical Development at Neurocrine Biosciences have generously agreed to lead our Scientific Program Committee for the ASENT Annual Meeting. |
CAREER CENTER
|
Clinical Trials Course Travel Grants
Featured Members |
NOT A MEMBER YET?
American Society for |
The American Society for Experimental Neurotherapeutics (ASENT) is a 501(c)3 non-profit organization.